LINC00460 and prostate cancer: It has been validated that LINC00460 functions as a competing endogenous RNA (ceRNA) in co-expression and promotes the malignant development of multiple cancers, including prostate cancer (37), skin cancer (38), hepatocellular cancer (39), colorectal cancer (40) and so on, except for RCC.